Its inhibition was shown to re-sensitise human and murine lung adenocarcinoma resistant to gefitinib, as well as human cell lines harbouring the osimertinib driver resistant mutation EGFR C797S, via the inhibition of HES1 protein by the binding of phospho-STAT3 to its promoter [136]. The gene discussed is EGFR; the disease is lung adenocarcinoma.